• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Influence of molar ratio on the combination effect of 5-fluorouracil with guanosine 5'-monophosphate on P388 and L1210 leukemias.

作者信息

Iigo M, Hoshi A

出版信息

Eur J Cancer Clin Oncol. 1984 Mar;20(3):411-5. doi: 10.1016/0277-5379(84)90089-0.

DOI:10.1016/0277-5379(84)90089-0
PMID:6323189
Abstract

To obtain more effective treatment with the combination of 5-fluorouracil (FUra) and guanosine 5'-monophosphate (GMP), the influence of the time interval between FUra and GMP administration and of the molar ratio of GMP to FUra on the effect on P388 murine leukemia were investigated. The antitumor activity of FUra was significantly potentiated when GMP was administered either 0-60 min before or 5 min after FUra. The potentiated increase in lifespan (ILS) was almost the same as after simultaneous injection of the two agents. Coadministration of FUra and GMP increased the antitumor activity as compared with the respective dose of FUra alone in a treatment schedule of either day 1 only or days 1-9. The multiple-dose regimen (days 1-9) was more effective than a single high-dose regimen, and a GMP/FUra molar ratio of 4 seems to achieve the best therapeutic results against P388 leukemia. Daily simultaneous administration of FUra and GMP on days 1-9 also resulted in a significant increase in the antitumor activity against L1210 Leukemia as compared with FUra alone.

摘要

相似文献

1
Influence of molar ratio on the combination effect of 5-fluorouracil with guanosine 5'-monophosphate on P388 and L1210 leukemias.
Eur J Cancer Clin Oncol. 1984 Mar;20(3):411-5. doi: 10.1016/0277-5379(84)90089-0.
2
Potentiation of the chemotherapeutic effect of 5-fluorouracil by combination with guanosine 5'-monophosphate.
Gan. 1983 Apr;74(2):291-8.
3
Schedule-dependent antitumor and toxic effects of thymidine and 5-fluorouracil in AKR and L1210 leukemias.
Cancer Chemother Pharmacol. 1986;18(2):101-4. doi: 10.1007/BF00262276.
4
Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia.
Cancer Chemother Pharmacol. 1984;13(2):86-90. doi: 10.1007/BF00257120.
5
Combination of 5-fluorouracil and cyclophosphamide in L1210 and P388 leukemias with changes in optimum treatments as a function of the age of the L1210 tumor at first treatment.
Cancer Invest. 1987;5(6):523-33. doi: 10.3109/07357908709020311.
6
Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.
Cancer Chemother Pharmacol. 1987;19(1):61-4. doi: 10.1007/BF00296258.
7
Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388.吉西他滨(2',2'-二氟脱氧胞苷)与2-氯脱氧腺苷对小鼠白血病L1210和P388的相加作用。
Cancer Invest. 1999;17(2):95-101. doi: 10.1080/07357909909011722.
8
Inability of amphotericin B(Fungizone) or of sodium deoxycholate to alter natural drug resistance or sensitivity of transplanted murine leukemias.两性霉素B(Fungizone)或脱氧胆酸钠无法改变移植性小鼠白血病的天然耐药性或敏感性。
Indian J Physiol Pharmacol. 1984 Jan-Mar;28(1):21-6.
9
Potentiation of antitumor activity of 5-fluoro-2'-deoxyuridine by guanosine-5'-monophosphate.5'-磷酸鸟苷增强5-氟-2'-脱氧尿苷的抗肿瘤活性
J Pharmacobiodyn. 1984 Jan;7(1):67-9. doi: 10.1248/bpb1978.7.67.
10
[Effects of combination chemotherapy of MCNU with various anti-cancer agents].
Gan To Kagaku Ryoho. 1985 Feb;12(2):298-302.

引用本文的文献

1
Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia.
Cancer Chemother Pharmacol. 1984;13(2):86-90. doi: 10.1007/BF00257120.
2
Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.
Cancer Chemother Pharmacol. 1987;19(1):61-4. doi: 10.1007/BF00296258.